SK12752002A3 - Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy - Google Patents
Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy Download PDFInfo
- Publication number
- SK12752002A3 SK12752002A3 SK1275-2002A SK12752002A SK12752002A3 SK 12752002 A3 SK12752002 A3 SK 12752002A3 SK 12752002 A SK12752002 A SK 12752002A SK 12752002 A3 SK12752002 A3 SK 12752002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- alkyl
- substituted
- aryl
- alkoxy
- Prior art date
Links
- 102000000019 Sterol Esterase Human genes 0.000 title claims abstract description 16
- 108010055297 Sterol Esterase Proteins 0.000 title claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 6
- -1 2-oxo-pyrrolidin-1-yl Chemical group 0.000 claims abstract description 110
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 35
- 150000002367 halogens Chemical class 0.000 claims abstract description 35
- 239000001257 hydrogen Substances 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 21
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 11
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 7
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims abstract description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 4
- 239000004305 biphenyl Substances 0.000 claims abstract description 3
- 235000010290 biphenyl Nutrition 0.000 claims abstract description 3
- 125000006267 biphenyl group Chemical group 0.000 claims abstract description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 2
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 150000004651 carbonic acid esters Chemical class 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract description 3
- 125000006702 (C1-C18) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 abstract 1
- 102100026020 Hormone-sensitive lipase Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 66
- 230000008018 melting Effects 0.000 description 66
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000004202 carbamide Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 9
- 150000004702 methyl esters Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- WVEMHEUXDRVXJO-UHFFFAOYSA-N 3-(4-amino-3-methylphenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(N)C(C)=C1 WVEMHEUXDRVXJO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 229950000964 pepstatin Drugs 0.000 description 4
- 108010091212 pepstatin Proteins 0.000 description 4
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- GYGWEMDUPYNZLJ-UHFFFAOYSA-N 3-(4-aminophenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(N)C=C1 GYGWEMDUPYNZLJ-UHFFFAOYSA-N 0.000 description 3
- 108010087765 Antipain Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- RKENPFBMIMYICS-UHFFFAOYSA-N [4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid Chemical compound O=C1OC(OC)=NN1C1=CC=C(NC(O)=O)C(C)=C1 RKENPFBMIMYICS-UHFFFAOYSA-N 0.000 description 3
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- RERPRXPTVXLOFR-UHFFFAOYSA-N (2-methyl-4-nitrophenyl)hydrazine Chemical compound CC1=CC([N+]([O-])=O)=CC=C1NN RERPRXPTVXLOFR-UHFFFAOYSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- GGWFTNFAHXOEBR-UHFFFAOYSA-N 4-(4-chlorophenoxy)-3-nitroaniline Chemical compound [O-][N+](=O)C1=CC(N)=CC=C1OC1=CC=C(Cl)C=C1 GGWFTNFAHXOEBR-UHFFFAOYSA-N 0.000 description 2
- KFIXQXHBBYKXBJ-UHFFFAOYSA-N 5-methoxy-3-(4-nitrophenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C([N+]([O-])=O)C=C1 KFIXQXHBBYKXBJ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 229940072033 potash Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- JBFZYCIJRNJFOG-UHFFFAOYSA-N (2-chloro-4-nitrophenyl)hydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1Cl JBFZYCIJRNJFOG-UHFFFAOYSA-N 0.000 description 1
- JQHJAEWDKPWZLC-UHFFFAOYSA-N (2-chlorophenyl)methyl n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamate Chemical compound O=C1OC(OC)=NN1C(C=C1C)=CC=C1NC(=O)OCC1=CC=CC=C1Cl JQHJAEWDKPWZLC-UHFFFAOYSA-N 0.000 description 1
- AJGBQAAXUVSBCH-UHFFFAOYSA-N (3,4,5-trifluorophenyl)methanamine Chemical compound NCC1=CC(F)=C(F)C(F)=C1 AJGBQAAXUVSBCH-UHFFFAOYSA-N 0.000 description 1
- INDBNDHPIXAFCP-UHFFFAOYSA-N (3-fluoro-4-nitrophenyl)hydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C(F)=C1 INDBNDHPIXAFCP-UHFFFAOYSA-N 0.000 description 1
- LJZQXGVKYRUBFR-UHFFFAOYSA-N (3-methyl-4-nitrophenyl)hydrazine Chemical compound CC1=CC(NN)=CC=C1[N+]([O-])=O LJZQXGVKYRUBFR-UHFFFAOYSA-N 0.000 description 1
- BMYRPSTYJKIUHG-UHFFFAOYSA-N (4-chlorophenyl)methyl n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]carbamate Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)OCC1=CC=C(Cl)C=C1 BMYRPSTYJKIUHG-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- OQEWCTIGTWIINY-UHFFFAOYSA-N 1-butyl-3-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]urea Chemical compound C1=CC(NC(=O)NCCCC)=CC=C1N1C(=O)OC(OC)=N1 OQEWCTIGTWIINY-UHFFFAOYSA-N 0.000 description 1
- BFCFYVKQTRLZHA-UHFFFAOYSA-N 1-chloro-2-nitrobenzene Chemical class [O-][N+](=O)C1=CC=CC=C1Cl BFCFYVKQTRLZHA-UHFFFAOYSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- KHSYYLCXQKCYQX-UHFFFAOYSA-N 1-naphthalen-2-ylethanamine Chemical compound C1=CC=CC2=CC(C(N)C)=CC=C21 KHSYYLCXQKCYQX-UHFFFAOYSA-N 0.000 description 1
- DEVNNJDTXHGNNI-UHFFFAOYSA-N 1-phenylethyl N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamate Chemical compound C1(=CC=CC=C1)C(C)OC(NC1=C(C=C(C=C1)N1C(OC(=N1)OC)=O)C)=O DEVNNJDTXHGNNI-UHFFFAOYSA-N 0.000 description 1
- OXUQBVNPZWAXIS-UHFFFAOYSA-N 2,2,2-trifluoroethyl n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamate Chemical compound O=C1OC(OC)=NN1C1=CC=C(NC(=O)OCC(F)(F)F)C(C)=C1 OXUQBVNPZWAXIS-UHFFFAOYSA-N 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- JJDJYSFCNJXKBG-UHFFFAOYSA-N 2-(4-chlorophenoxy)-n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]-2-methylpropanamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JJDJYSFCNJXKBG-UHFFFAOYSA-N 0.000 description 1
- ZBLFPKVZIWABFU-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[2-[(4-fluorophenyl)methoxy]-4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]acetamide Chemical compound O=C1OC(OC)=NN1C(C=C1OCC=2C=CC(F)=CC=2)=CC=C1NC(=O)CC1=CC=C(Cl)C=C1 ZBLFPKVZIWABFU-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- NONJEXXMLIRAIS-UHFFFAOYSA-N 2-[[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamoylamino]-3-methylbutanoic acid Chemical compound COC1=NN(C(O1)=O)C1=CC(=C(C=C1)NC(NC(C(=O)O)C(C)C)=O)C NONJEXXMLIRAIS-UHFFFAOYSA-N 0.000 description 1
- GQTBZFPQUURUIQ-UHFFFAOYSA-N 2-chloro-n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]benzenesulfonamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=CC=C1Cl GQTBZFPQUURUIQ-UHFFFAOYSA-N 0.000 description 1
- AZHADHQYJXQOKG-UHFFFAOYSA-N 2-fluoro-4-[(4-fluorophenyl)methoxy]-1-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC=C1OCC1=CC=C(F)C=C1 AZHADHQYJXQOKG-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 1
- KSAWBHYENZIVKW-UHFFFAOYSA-N 3-(2-chloro-4-nitrophenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C([N+]([O-])=O)C=C1Cl KSAWBHYENZIVKW-UHFFFAOYSA-N 0.000 description 1
- YUDKZZOTLXQBLL-UHFFFAOYSA-N 3-(3-aminophenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(N)=C1 YUDKZZOTLXQBLL-UHFFFAOYSA-N 0.000 description 1
- WKFJJXQUEJNKLA-UHFFFAOYSA-N 3-(3-fluoro-4-nitrophenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C([N+]([O-])=O)C(F)=C1 WKFJJXQUEJNKLA-UHFFFAOYSA-N 0.000 description 1
- DOUHTUMKVIOSOK-UHFFFAOYSA-N 3-(4-amino-2-chlorophenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(N)C=C1Cl DOUHTUMKVIOSOK-UHFFFAOYSA-N 0.000 description 1
- GOGMVJGTCRDFOD-UHFFFAOYSA-N 3-(4-amino-2-methylphenyl)-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(N)C=C1C GOGMVJGTCRDFOD-UHFFFAOYSA-N 0.000 description 1
- RHMCSRPITHPKGN-UHFFFAOYSA-N 3-[3-(benzylamino)phenyl]-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(NCC=2C=CC=CC=2)=C1 RHMCSRPITHPKGN-UHFFFAOYSA-N 0.000 description 1
- YWZXYURCRBPLHI-UHFFFAOYSA-N 3-[3-(dibenzylamino)phenyl]-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=CC(N(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 YWZXYURCRBPLHI-UHFFFAOYSA-N 0.000 description 1
- KHICPASJCVEVBY-UHFFFAOYSA-N 3-[3-[(4-fluorophenyl)methoxy]-4-nitrophenyl]-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C([N+]([O-])=O)C(OCC=2C=CC(F)=CC=2)=C1 KHICPASJCVEVBY-UHFFFAOYSA-N 0.000 description 1
- DAWQRVSHGIJNMJ-UHFFFAOYSA-N 3-[4-(2,5-dimethylpyrrol-1-yl)-3-methylphenyl]-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(N2C(=CC=C2C)C)C(C)=C1 DAWQRVSHGIJNMJ-UHFFFAOYSA-N 0.000 description 1
- TVXVKKORSQUXPI-UHFFFAOYSA-N 3-[4-(3,3-dichlorononylamino)phenyl]-5-methoxy-1,3,4-oxadiazol-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(NCCC(Cl)(Cl)CCCCCC)=CC=C1N1C(=O)OC(OC)=N1 TVXVKKORSQUXPI-UHFFFAOYSA-N 0.000 description 1
- CBCJGEIMGVHHLP-UHFFFAOYSA-N 3-[4-(dimethylamino)-3-methylphenyl]-5-methoxy-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(N(C)C)C(C)=C1 CBCJGEIMGVHHLP-UHFFFAOYSA-N 0.000 description 1
- FKMKWWDPMLXNJX-UHFFFAOYSA-N 3-[4-[(2-chloroquinolin-3-yl)methylamino]phenyl]-5-methoxy-1,3,4-oxadiazol-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1OC(OC)=NN1C(C=C1)=CC=C1NCC1=CC2=CC=CC=C2N=C1Cl FKMKWWDPMLXNJX-UHFFFAOYSA-N 0.000 description 1
- UFGWOMDPBPFTHC-UHFFFAOYSA-N 3-[4-[(3-ethoxy-4-methoxyphenyl)methylamino]phenyl]-5-methoxy-1,3,4-oxadiazol-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(OC)C(OCC)=CC(CNC=2C=CC(=CC=2)N2C(OC(OC)=N2)=O)=C1 UFGWOMDPBPFTHC-UHFFFAOYSA-N 0.000 description 1
- MJUPORMFOYTGLU-UHFFFAOYSA-N 3-[4-[(5-bromo-2-fluorophenyl)methylamino]phenyl]-5-methoxy-1,3,4-oxadiazol-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1OC(OC)=NN1C(C=C1)=CC=C1NCC1=CC(Br)=CC=C1F MJUPORMFOYTGLU-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UCPUXAMMMQGVQR-UHFFFAOYSA-N 4-[[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]carbamoyl]benzenesulfonyl fluoride Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)C1=CC=C(S(F)(=O)=O)C=C1 UCPUXAMMMQGVQR-UHFFFAOYSA-N 0.000 description 1
- LZJVSPPXXGXGQL-UHFFFAOYSA-N 4-aminobenzenecarbothioamide Chemical compound NC(=S)C1=CC=C(N)C=C1 LZJVSPPXXGXGQL-UHFFFAOYSA-N 0.000 description 1
- PNNBYBPJSUZJRK-UHFFFAOYSA-N 4-butyl-n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]benzenesulfonamide Chemical compound C1=CC(CCCC)=CC=C1S(=O)(=O)NC1=CC=C(N2C(OC(OC)=N2)=O)C=C1 PNNBYBPJSUZJRK-UHFFFAOYSA-N 0.000 description 1
- QTKNENFABYLONL-UHFFFAOYSA-N 4-chloro-n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]benzenesulfonamide Chemical compound O=C1OC(OC)=NN1C(C=C1C)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 QTKNENFABYLONL-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- FPWNLURCHDRMHC-UHFFFAOYSA-N 4-chlorobiphenyl Chemical group C1=CC(Cl)=CC=C1C1=CC=CC=C1 FPWNLURCHDRMHC-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical compound CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
- LLIOADBCFIXIEU-UHFFFAOYSA-N 4-fluoro-3-nitroaniline Chemical compound NC1=CC=C(F)C([N+]([O-])=O)=C1 LLIOADBCFIXIEU-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RHOWZICICYPGEM-UHFFFAOYSA-N 4-tert-butyl-n-[2-fluoro-4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]benzamide Chemical compound O=C1OC(OC)=NN1C(C=C1F)=CC=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 RHOWZICICYPGEM-UHFFFAOYSA-N 0.000 description 1
- QPUXQWSDBKIGCJ-UHFFFAOYSA-N 4-tert-butyl-n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]benzamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 QPUXQWSDBKIGCJ-UHFFFAOYSA-N 0.000 description 1
- JDTASEYRNDUTJV-UHFFFAOYSA-N 5-chloro-1-benzofuran-2-carboxamide Chemical compound ClC1=CC=C2OC(C(=O)N)=CC2=C1 JDTASEYRNDUTJV-UHFFFAOYSA-N 0.000 description 1
- AFVHKRIIUJGSCK-UHFFFAOYSA-N 5-methoxy-3-(2-methyl-4-nitrophenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C([N+]([O-])=O)C=C1C AFVHKRIIUJGSCK-UHFFFAOYSA-N 0.000 description 1
- ACTWOEKPOZGHEQ-UHFFFAOYSA-N 5-methoxy-3-(3-methyl-4-nitrophenyl)-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C([N+]([O-])=O)C(C)=C1 ACTWOEKPOZGHEQ-UHFFFAOYSA-N 0.000 description 1
- FTOULQMQYDOUCP-UHFFFAOYSA-N 5-methoxy-3-[3-(2-phenylmethoxyethylamino)phenyl]-1,3,4-oxadiazol-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1OC(OC)=NN1C1=CC=CC(NCCOCC=2C=CC=CC=2)=C1 FTOULQMQYDOUCP-UHFFFAOYSA-N 0.000 description 1
- CFTRDLYCSWTIAM-UHFFFAOYSA-N 5-methoxy-3-[3-methyl-4-(4-oxopent-2-en-2-ylamino)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C1=CC=C(NC(C)=CC(C)=O)C(C)=C1 CFTRDLYCSWTIAM-UHFFFAOYSA-N 0.000 description 1
- FPAWEKPSCCLOCN-UHFFFAOYSA-N 5-methoxy-3-[4-(thiophen-3-ylmethylamino)phenyl]-1,3,4-oxadiazol-2-one Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NCC1=CSC=C1 FPAWEKPSCCLOCN-UHFFFAOYSA-N 0.000 description 1
- JOPCCIBRUGRSQJ-UHFFFAOYSA-N 5-methoxy-3-[4-[(2,3,5-trichlorophenyl)methylamino]phenyl]-1,3,4-oxadiazol-2-one 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1OC(OC)=NN1C(C=C1)=CC=C1NCC1=CC(Cl)=CC(Cl)=C1Cl JOPCCIBRUGRSQJ-UHFFFAOYSA-N 0.000 description 1
- RJNMAVILZOIHES-UHFFFAOYSA-N 5-methoxy-3h-1,3,4-oxadiazol-2-one Chemical compound COC1=NN=C(O)O1 RJNMAVILZOIHES-UHFFFAOYSA-N 0.000 description 1
- SHKWSBAVRQZYLE-UHFFFAOYSA-N 5-oxo-5-phenylpentanoic acid Chemical compound OC(=O)CCCC(=O)C1=CC=CC=C1 SHKWSBAVRQZYLE-UHFFFAOYSA-N 0.000 description 1
- UUTYLSKGIIEBRI-UHFFFAOYSA-N 5-phenoxy-3h-1,3,4-oxadiazol-2-one Chemical class O1C(=O)NN=C1OC1=CC=CC=C1 UUTYLSKGIIEBRI-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DVICEUBJHKSBGW-UHFFFAOYSA-N BrC1=CC=C(C=C1)NC(=O)NC1=CC(=CC=C1)N1C(OC(=N1)OC)=O Chemical compound BrC1=CC=C(C=C1)NC(=O)NC1=CC(=CC=C1)N1C(OC(=N1)OC)=O DVICEUBJHKSBGW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZQBUHMHHKFDTNJ-UHFFFAOYSA-N C1(CCCC2=CC=CC=C12)OC(NC1=C(C=C(C=C1)N1C(OC(=N1)OC)=O)C)=O Chemical compound C1(CCCC2=CC=CC=C12)OC(NC1=C(C=C(C=C1)N1C(OC(=N1)OC)=O)C)=O ZQBUHMHHKFDTNJ-UHFFFAOYSA-N 0.000 description 1
- QTENHWTVRQKWRI-UHFFFAOYSA-N CAY10499 Chemical compound O=C1OC(OC)=NN1C(C=C1C)=CC=C1NC(=O)OCC1=CC=CC=C1 QTENHWTVRQKWRI-UHFFFAOYSA-N 0.000 description 1
- WVCIKVCSLPNIKX-UHFFFAOYSA-N CN1CCC(CC1)OC(NC1=C(C=C(C=C1)N1C(OC(=N1)OC)=O)C)=O Chemical compound CN1CCC(CC1)OC(NC1=C(C=C(C=C1)N1C(OC(=N1)OC)=O)C)=O WVCIKVCSLPNIKX-UHFFFAOYSA-N 0.000 description 1
- VZSOZUSQZDYJRJ-UHFFFAOYSA-N COC1=NN(C(O1)=O)C1=CC=C(C=C1)NC(=O)C=1OC2=C(C1)C=C(C=C2)Cl Chemical compound COC1=NN(C(O1)=O)C1=CC=C(C=C1)NC(=O)C=1OC2=C(C1)C=C(C=C2)Cl VZSOZUSQZDYJRJ-UHFFFAOYSA-N 0.000 description 1
- NIKGKDXQXMNRIB-UHFFFAOYSA-N COC1=NN(C(O1)=O)C1=CC=C(C=C1)NC(=O)NC1=CC=C(C=C1)OC1=CC=CC=C1 Chemical compound COC1=NN(C(O1)=O)C1=CC=C(C=C1)NC(=O)NC1=CC=C(C=C1)OC1=CC=CC=C1 NIKGKDXQXMNRIB-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- TWNYGHRYDMGAAI-UHFFFAOYSA-N FC1=C(C(=CC=C1)F)NC(=O)NC1=CC=C(C=C1)N1C(OC(=N1)OC)=O Chemical compound FC1=C(C(=CC=C1)F)NC(=O)NC1=CC=C(C=C1)N1C(OC(=N1)OC)=O TWNYGHRYDMGAAI-UHFFFAOYSA-N 0.000 description 1
- XISUBGCTLLFYCT-UHFFFAOYSA-N FC1=C(C=CC(=C1)F)NC(=O)NC1=CC=C(C=C1)N1C(OC(=N1)OC)=O Chemical compound FC1=C(C=CC(=C1)F)NC(=O)NC1=CC=C(C=C1)N1C(OC(=N1)OC)=O XISUBGCTLLFYCT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- FLDPONQJBLVNOW-UHFFFAOYSA-N N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]-2-(2-phenylethyl)benzamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 FLDPONQJBLVNOW-UHFFFAOYSA-N 0.000 description 1
- MMEJRNBJICMZEY-UHFFFAOYSA-N N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]-2-(4-methoxyphenoxy)-5-nitrobenzamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)C1=CC([N+]([O-])=O)=CC=C1OC1=CC=C(OC)C=C1 MMEJRNBJICMZEY-UHFFFAOYSA-N 0.000 description 1
- VKFNZPCOCZANPX-UHFFFAOYSA-N N-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]-2-(4-phenylmethoxyphenyl)acetamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)CC(C=C1)=CC=C1OCC1=CC=CC=C1 VKFNZPCOCZANPX-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- IUASHTHTYJCWLY-UHFFFAOYSA-N [3-[(4-fluorophenyl)methoxy]-2-nitrophenyl]hydrazine Chemical compound NNC1=CC=CC(OCC=2C=CC(F)=CC=2)=C1[N+]([O-])=O IUASHTHTYJCWLY-UHFFFAOYSA-N 0.000 description 1
- YJKPEQVLHCYYRF-UHFFFAOYSA-N [3-[(4-fluorophenyl)methoxy]-4-nitrophenyl]hydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C(OCC=2C=CC(F)=CC=2)=C1 YJKPEQVLHCYYRF-UHFFFAOYSA-N 0.000 description 1
- GFTVEAPFCLTYQF-UHFFFAOYSA-N [4-(4-chlorophenoxy)-3-nitrophenyl]hydrazine Chemical compound [O-][N+](=O)C1=CC(NN)=CC=C1OC1=CC=C(Cl)C=C1 GFTVEAPFCLTYQF-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QBBJFYQPYXKIEB-UHFFFAOYSA-N benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N#CC1=CC=CC=C1 QBBJFYQPYXKIEB-UHFFFAOYSA-N 0.000 description 1
- UNHPWEMXORMGDT-UHFFFAOYSA-N benzyl n-[2-methyl-4-[5-[(2-methylpropan-2-yl)oxy]-2-oxo-1,3,4-oxadiazol-3-yl]phenyl]carbamate Chemical compound CC1=CC(N2C(OC(OC(C)(C)C)=N2)=O)=CC=C1NC(=O)OCC1=CC=CC=C1 UNHPWEMXORMGDT-UHFFFAOYSA-N 0.000 description 1
- KXZFTXBIIXFRJG-UHFFFAOYSA-N benzyl n-[3-chloro-4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]carbamate Chemical compound O=C1OC(OC)=NN1C(C(=C1)Cl)=CC=C1NC(=O)OCC1=CC=CC=C1 KXZFTXBIIXFRJG-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- MLKBXYOGOGIRQE-UHFFFAOYSA-N butyl n-[2-methyl-4-(2-oxo-5-propan-2-yloxy-1,3,4-oxadiazol-3-yl)phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCCC)=CC=C1N1C(=O)OC(OC(C)C)=N1 MLKBXYOGOGIRQE-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- MTMNJFGEKOYMIV-UHFFFAOYSA-N carbonyl dichloride;toluene Chemical compound ClC(Cl)=O.CC1=CC=CC=C1 MTMNJFGEKOYMIV-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000005171 halobenzenes Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- PBNRFAMNCFKUJO-UHFFFAOYSA-N n-[2-fluoro-4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]-4-(trifluoromethyl)benzamide Chemical compound O=C1OC(OC)=NN1C(C=C1F)=CC=C1NC(=O)C1=CC=C(C(F)(F)F)C=C1 PBNRFAMNCFKUJO-UHFFFAOYSA-N 0.000 description 1
- QHTWDXCMTFVRQZ-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]-2,2-dimethylpropanamide Chemical compound O=C1OC(OC)=NN1C1=CC=C(NC(=O)C(C)(C)C)C(C)=C1 QHTWDXCMTFVRQZ-UHFFFAOYSA-N 0.000 description 1
- KPMUKLJFNDTDSE-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]naphthalene-1-sulfonamide Chemical compound O=C1OC(OC)=NN1C(C=C1C)=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CC=C12 KPMUKLJFNDTDSE-UHFFFAOYSA-N 0.000 description 1
- JPUPNIQGJKJSCS-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]octanamide Chemical compound C1=C(C)C(NC(=O)CCCCCCC)=CC=C1N1C(=O)OC(OC)=N1 JPUPNIQGJKJSCS-UHFFFAOYSA-N 0.000 description 1
- ANSXSXRHYSZEFR-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]piperidine-1-carboxamide Chemical compound O=C1OC(OC)=NN1C(C=C1C)=CC=C1NC(=O)N1CCCCC1 ANSXSXRHYSZEFR-UHFFFAOYSA-N 0.000 description 1
- KEZYVRNCEKIFCI-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-phenylmethoxyphenyl]-4-(trifluoromethyl)benzamide Chemical compound O=C1OC(OC)=NN1C(C=C1OCC=2C=CC=CC=2)=CC=C1NC(=O)C1=CC=C(C(F)(F)F)C=C1 KEZYVRNCEKIFCI-UHFFFAOYSA-N 0.000 description 1
- GVODTCVMWJMRSF-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-3-methylphenyl]-4-(trifluoromethoxy)benzamide Chemical compound O=C1OC(OC)=NN1C(C(=C1)C)=CC=C1NC(=O)C1=CC=C(OC(F)(F)F)C=C1 GVODTCVMWJMRSF-UHFFFAOYSA-N 0.000 description 1
- JMWJWFLOJPOSAJ-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]-3,3,3-triphenylpropanamide Chemical compound O=C1OC(OC)=NN1C(C=C1)=CC=C1NC(=O)CC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 JMWJWFLOJPOSAJ-UHFFFAOYSA-N 0.000 description 1
- XLQHJWUOGBLYJJ-UHFFFAOYSA-N n-[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)phenyl]propane-2-sulfonamide Chemical compound O=C1OC(OC)=NN1C1=CC=C(NS(=O)(=O)C(C)C)C=C1 XLQHJWUOGBLYJJ-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- SXVRECLPTCOMIA-UHFFFAOYSA-N quinoline-8-sulfonic acid Chemical compound C1=CN=C2C(S(=O)(=O)O)=CC=CC2=C1 SXVRECLPTCOMIA-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2000110968 DE10010968A1 (de) | 2000-03-07 | 2000-03-07 | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| DE2001102265 DE10102265C1 (de) | 2001-01-18 | 2001-01-18 | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| PCT/EP2001/001898 WO2001066531A1 (de) | 2000-03-07 | 2001-02-20 | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK12752002A3 true SK12752002A3 (sk) | 2003-04-01 |
Family
ID=26004720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1275-2002A SK12752002A3 (sk) | 2000-03-07 | 2001-02-20 | Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6369088B2 (xx) |
| EP (1) | EP1263745B1 (xx) |
| JP (1) | JP2003525931A (xx) |
| KR (1) | KR100790763B1 (xx) |
| CN (1) | CN1261419C (xx) |
| AR (1) | AR027611A1 (xx) |
| AT (1) | ATE267184T1 (xx) |
| AU (1) | AU784827B2 (xx) |
| BR (1) | BR0108974A (xx) |
| CA (1) | CA2401953A1 (xx) |
| DE (1) | DE50102325D1 (xx) |
| DK (1) | DK1263745T3 (xx) |
| EE (1) | EE04877B1 (xx) |
| ES (1) | ES2218383T3 (xx) |
| HK (1) | HK1054036B (xx) |
| HR (1) | HRP20020732A2 (xx) |
| HU (1) | HUP0302772A3 (xx) |
| IL (1) | IL151518A (xx) |
| MX (1) | MXPA02008038A (xx) |
| NO (1) | NO323483B1 (xx) |
| NZ (1) | NZ521207A (xx) |
| PL (1) | PL359702A1 (xx) |
| PT (1) | PT1263745E (xx) |
| RU (1) | RU2281283C2 (xx) |
| SK (1) | SK12752002A3 (xx) |
| TR (1) | TR200401217T4 (xx) |
| WO (1) | WO2001066531A1 (xx) |
| YU (1) | YU57802A (xx) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| US6900233B2 (en) | 2002-02-28 | 2005-05-31 | Aventis Pharma Deutschland Gmbh | Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof |
| DE10208987A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen |
| DE10208986A1 (de) * | 2002-02-28 | 2003-09-11 | Aventis Pharma Gmbh | Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase |
| US20030236288A1 (en) * | 2002-02-28 | 2003-12-25 | Karl Schoenafinger | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| US20090082435A1 (en) * | 2005-04-28 | 2009-03-26 | The Regents Of The University Of California | Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders |
| CN101225085B (zh) * | 2007-01-17 | 2011-09-21 | 天津天士力集团有限公司 | 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途 |
| TW201033163A (en) * | 2008-10-20 | 2010-09-16 | Sumitomo Chemical Co | Method for manufacturing oxadiazolinone compound and intermediate thereof |
| TW201028406A (en) | 2008-12-23 | 2010-08-01 | Bial Portela & Ca Sa | 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use |
| JP5761173B2 (ja) * | 2010-03-04 | 2015-08-12 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| ES2634716T3 (es) | 2011-05-31 | 2017-09-28 | Celgene International Ii Sàrl | Nuevos estabilizantes y moduladores del receptor GLP-1 |
| JP6061949B2 (ja) | 2011-12-12 | 2017-01-18 | レセプトス エルエルシー | 糖尿病などの疾患の治療のためのｇｌｐ−１受容体モジュレーターとして作用する４つの環を含むカルボン酸誘導体 |
| CN109867630A (zh) | 2013-06-11 | 2019-06-11 | 赛尔基因第二国际有限公司 | 新型glp-1受体调节剂 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
| EP3172199B1 (en) | 2014-07-25 | 2020-07-01 | Celgene International II Sarl | Pyrimidine derivatives as glp-1 receptor modulators |
| EP3230276B1 (en) | 2014-12-10 | 2020-09-02 | Celgene International II Sarl | Glp-1 receptor modulators |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| CN108863774A (zh) * | 2018-06-09 | 2018-11-23 | 石家庄市绿丰化工有限公司 | 一种2,4-二氯苯乙酰氯合成的方法 |
| CN113227093A (zh) | 2018-11-14 | 2021-08-06 | 阿尔塔万特科学公司 | 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4076824A (en) | 1975-02-03 | 1978-02-28 | Rhone-Poulenc Industries | Anthelmintic oxadiazolinone derivatives |
| FR2299028A1 (fr) | 1975-02-03 | 1976-08-27 | Rhone Poulenc Ind | Nouvea |
| FR2299328A1 (fr) | 1975-02-03 | 1976-08-27 | Rhone Poulenc Ind | Derives de l'alcoyloxy-5 phenyl-3 oxyde azo |
| DK156439C (da) | 1980-09-15 | 1990-01-22 | Shell Int Research | 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer |
| EP0067471B1 (en) | 1981-06-15 | 1985-11-06 | Shell Internationale Researchmaatschappij B.V. | 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates |
| US5236939A (en) | 1989-09-23 | 1993-08-17 | Bayer Aktiengesellschaft | Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites |
| DE3931843A1 (de) | 1989-09-23 | 1991-04-04 | Bayer Ag | Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
-
2001
- 2001-02-20 NZ NZ521207A patent/NZ521207A/en unknown
- 2001-02-20 CN CNB018062156A patent/CN1261419C/zh not_active Expired - Fee Related
- 2001-02-20 HU HU0302772A patent/HUP0302772A3/hu unknown
- 2001-02-20 TR TR2004/01217T patent/TR200401217T4/xx unknown
- 2001-02-20 HK HK03106394.6A patent/HK1054036B/zh not_active IP Right Cessation
- 2001-02-20 YU YU57802A patent/YU57802A/sh unknown
- 2001-02-20 PL PL35970201A patent/PL359702A1/xx not_active IP Right Cessation
- 2001-02-20 DK DK01905805T patent/DK1263745T3/da active
- 2001-02-20 DE DE50102325T patent/DE50102325D1/de not_active Expired - Lifetime
- 2001-02-20 EE EEP200200498A patent/EE04877B1/xx not_active IP Right Cessation
- 2001-02-20 AU AU33787/01A patent/AU784827B2/en not_active Ceased
- 2001-02-20 HR HRP20020732 patent/HRP20020732A2/hr not_active Application Discontinuation
- 2001-02-20 KR KR1020027011634A patent/KR100790763B1/ko not_active Expired - Fee Related
- 2001-02-20 CA CA002401953A patent/CA2401953A1/en not_active Abandoned
- 2001-02-20 RU RU2002126556/04A patent/RU2281283C2/ru not_active IP Right Cessation
- 2001-02-20 JP JP2001565347A patent/JP2003525931A/ja not_active Abandoned
- 2001-02-20 PT PT01905805T patent/PT1263745E/pt unknown
- 2001-02-20 IL IL151518A patent/IL151518A/en not_active IP Right Cessation
- 2001-02-20 ES ES01905805T patent/ES2218383T3/es not_active Expired - Lifetime
- 2001-02-20 BR BR0108974-9A patent/BR0108974A/pt not_active IP Right Cessation
- 2001-02-20 EP EP01905805A patent/EP1263745B1/de not_active Expired - Lifetime
- 2001-02-20 SK SK1275-2002A patent/SK12752002A3/sk unknown
- 2001-02-20 WO PCT/EP2001/001898 patent/WO2001066531A1/de not_active Ceased
- 2001-02-20 AT AT01905805T patent/ATE267184T1/de not_active IP Right Cessation
- 2001-02-20 MX MXPA02008038A patent/MXPA02008038A/es active IP Right Grant
- 2001-03-05 AR ARP010101037A patent/AR027611A1/es not_active Application Discontinuation
- 2001-03-06 US US09/799,082 patent/US6369088B2/en not_active Expired - Lifetime
-
2002
- 2002-09-03 NO NO20024201A patent/NO323483B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK12752002A3 (sk) | Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy | |
| CN1116287C (zh) | 用作钾通道调节剂的二苯基杂环化合物 | |
| EP1813606A1 (en) | Amide compound | |
| JP2003525931A6 (ja) | 置換された３−フェニル−５−アルコキシ−１，３，４−オキサジアゾール−２−オンおよびホルモン感受性リパーゼを阻害するためのその使用 | |
| JP2008523133A (ja) | Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体 | |
| KR20090014223A (ko) | 니코틴성 아세틸콜린 수용체 리간드로서의 2-페닐-5-아미노-1,3,4-옥사디아졸 및 그의 용도 | |
| RU2265600C2 (ru) | Замещенные 3-фенил-5-алкокси-1,3,4-оксадиазол-2-оны и их применение в качестве ингибиторов липазы | |
| MXPA04007480A (es) | Uso de 3-fenil-5-alcoxi-1,3,4-oxdiazol-2-onas sustituidas para producir medicamentos que inhiben la lipasa pancreatica. | |
| US20030236288A1 (en) | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | |
| US20030181433A1 (en) | Substituted 3-phenyl-5-alkoxy-3H- (1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof | |
| JP2005519085A (ja) | 置換３−フェニル−５−アルコキシ−１，３，４−オキサジアゾール−２−オン、これの製造方法および薬剤での使用 | |
| RS57802B1 (sr) | Ukrasni veštački nokti šake za višekratnu upotrebu | |
| DE10010968A1 (de) | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen | |
| HK1107091A (en) | Amide compound | |
| HK1022247A (en) | Diphenyl heterocycles as potassium channel modulators |